TY - JOUR
T1 - Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases
AU - Dadachova, Ekaterina
AU - Casadevall, Arturo
N1 - Funding Information:
The authors were supported by NIH grants 5U54AI057158-03, AI033142, AI033774 and HL059842 (AC), and AI60507 (ED).
PY - 2005/11
Y1 - 2005/11
N2 - The field of infectious diseases is in crisis and there is a need for strategies that can facilitate the rapid development of new antimicrobial agents. Radioimmunotherapy (RIT), a therapeutic modality originally developed for cancer treatment, has recently been suggested as a novel therapy for the treatment of a variety of infectious diseases. Because specific antibodies are used in RIT as delivery vehicles of cytocidal radiation, their molecular weight influences the nonspecific accumulation in infectious foci and blood clearance, and their affinity-specific accumulation of antibodies in infectious foci. Like the problems encountered in oncology, relevant variables in the development of RIT of infectious diseases include target antigen-shedding; delivering radionuclides to infectious foci in organs, abscesses, granulomas, heart and brain, and potential safety concerns. Dadachova and Casadevall anticipate that RIT can be developed for many types of infectious diseases, including microbes resistant to conventional antimicrobial therapy and agents of biological warfare.
AB - The field of infectious diseases is in crisis and there is a need for strategies that can facilitate the rapid development of new antimicrobial agents. Radioimmunotherapy (RIT), a therapeutic modality originally developed for cancer treatment, has recently been suggested as a novel therapy for the treatment of a variety of infectious diseases. Because specific antibodies are used in RIT as delivery vehicles of cytocidal radiation, their molecular weight influences the nonspecific accumulation in infectious foci and blood clearance, and their affinity-specific accumulation of antibodies in infectious foci. Like the problems encountered in oncology, relevant variables in the development of RIT of infectious diseases include target antigen-shedding; delivering radionuclides to infectious foci in organs, abscesses, granulomas, heart and brain, and potential safety concerns. Dadachova and Casadevall anticipate that RIT can be developed for many types of infectious diseases, including microbes resistant to conventional antimicrobial therapy and agents of biological warfare.
KW - Infectious diseases
KW - Monoclonal antibodies
KW - Radioimmunotherapy
KW - Scintigraphic imaging
UR - http://www.scopus.com/inward/record.url?scp=28244453324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28244453324&partnerID=8YFLogxK
U2 - 10.1517/17425247.2.6.1075
DO - 10.1517/17425247.2.6.1075
M3 - Review article
C2 - 16296810
AN - SCOPUS:28244453324
SN - 1742-5247
VL - 2
SP - 1075
EP - 1084
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 6
ER -
